

CORRECTION

Open Access

Correction: BiOsimilaRs in the management of anaemia secondary to chemotherapy in Haematology and Oncology: results of the ORHEO observational study

Mauricette Michallet^{1*}, Elisabeth Luporsi², Pierre Soubeyran³, Nadia Ali Amar⁴, Vincent Boulanger⁵, Miguel Carreiro⁶, Louis-Marie Dourthe⁷, Jean-Luc Labourey^{5,8}, Daniel Lepille⁹, Frédéric Maloisel⁷, Jean-Loup Mouysset¹⁰, Sophie Nahon¹¹, Bérengère Narciso¹², Pierre Nouyrigat¹³, Raouf Radji¹⁴, Nacéra Sakek¹⁵, Hélène Albrand¹⁶ and The ORHEO study group

Correction

After publication of this Research Article [1], we noted errors in Table 1, and in the rate of thromboembolic events (page 7). Specifically, in Table 1 the percentage of female and male patients were incorrectly given as 7% and 3% respectively. The correct figures are 48.6% female and 51.4% male (please see a corrected version of Table 1 below, and the Additional file 1). The correct rate of thromboembolic events is 3.49% (originally stated as 3.55%).

Table 1 Patient demographics

Characteristic	Value
Age, mean ± SD (years)	66.49 ± 11.77
Patients with solid tumours, mean (years)	65.76
Patients with lymphoma, mean (years)	68.59
Patients with myeloma, mean (years)	70.65
Female (%)	48.6
Male (%)	51.4
Hb, mean ± SD (g/dL)	9.59 ± 0.88
sBP, mean ± SD (mmHg)	125.75 ± 14.48
dBp, mean ± SD (mmHg)	74.18 ± 9.79
Malignancies, n (%)	2310 (100)
Solid tumours, n (%)	1838 (79.57)
Lymphoma, n (%)	301 (13.03)
Myeloma, n (%)	171 (7.40)
Height, mean ± SD (cm)	166.35 ± 8.72
Weight, mean ± SD (kg)	67.46 ± 14.23
BMI, mean ± SD (kg/m ²)	24.33 ± 4.62

BMI body mass index, *dBp* diastolic blood pressure, *Hb* haemoglobin, *sBP* systolic blood pressure, *SD* standard deviation.

* Correspondence: Mauricette.michallet@chu-lyon.fr

¹Centre Hospitalier Lyon Sud, Lyon, France

Full list of author information is available at the end of the article

Additional file

Additional file 1: Corrected version of article *BMC Cancer* 14:503.

Author details

¹Centre Hospitalier Lyon Sud, Lyon, France. ²Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France. ³Institut Bergonie, Bordeaux, France. ⁴Centre Hospitalier de Troyes, Troyes, France. ⁵Centre Hospitalier de Carcassonne, Carcassonne, France. ⁶Centre Hospitalier de Montauban, Montauban, France. ⁷Clinique Sainte Anne, Strasbourg, France. ⁸Polyclinique Montréal, Carcassonne, France. ⁹Clinique Pasteur, Evreux, France. ¹⁰Clinique Rambot-Provencale, Aix en Provence, France. ¹¹Centre Hospitalier d'Aix en Provence, Aix en Provence, France. ¹²Centre Hospitalier Régional Universitaire de Tours, Tours, France. ¹³Clinique du Cap d'Or, La Seyne sur Mer, France. ¹⁴Centre Frédéric JOLLIOT, Rouen, France. ¹⁵Centre Hospitalier de Montbéliard, Montbéliard, France. ¹⁶Laboratoire HOSPIRA France, MeudonLa Foret, France.

Received: 3 September 2014 Accepted: 18 September 2014

Published: 26 September 2014

Reference

1. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe L-M, Labourey J-L, Lepille D, Maloisel F, Mouysset J-L, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H: **BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.** *BMC Cancer* 2014, **14**:503.

doi:10.1186/1471-2407-14-720

Cite this article as: Michallet *et al.*: Correction: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. *BMC Cancer* 2014 **14**:720.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

